On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) will convene at the FDA White Oak Campus in Silver Spring, Maryland, to review whether seven research peptides should be recommended for addition to the 503A Bulk Drug Substances List. The compounds under review are BPC-157, TB-500 (Thymosin Beta-4 fragment), MOTS-c, KPV, DSIP (Delta Sleep Inducing Peptide), Semax, and Epitalon.

This is the most consequential regulatory hearing for the peptide research community in 2026. If you want lawful, quality-verified compounding access to any of these compounds — or if you want your voice in the process — there are two deadlines to know: oral testimony registration closes June 30, 2026, and written public comments close July 9, 2026.

What the 503A Bulks List Is and Why It Matters

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies can prepare individualized prescriptions using bulk drug substances — but only if those substances appear on the FDA’s approved bulks list (Category 1), or meet other narrow criteria. For years, the peptides listed above existed in a grey zone: they were nominally prohibited from compounding by their placement on the Category 2 “Do Not Compound” list, meaning they could not be legally prescribed and compounded for patients.

In April 2026, the FDA removed twelve peptides — including all seven above — from Category 2. That removal is meaningful: it signals the FDA no longer considers these compounds to present significant safety risks at the compounding level. But it does not authorize compounding. The peptides now exist in a regulatory grey zone — off the prohibited list, but not yet on the approved list.

The PCAC hearing on July 23–24 is the process by which the FDA determines whether to move them from grey zone to formal authorization. A positive PCAC recommendation initiates FDA rulemaking to add a substance to the 503A bulks list — which would give licensed 503A compounding pharmacies the legal basis to compound these peptides for individual patients with valid prescriptions.

The Day-by-Day Schedule

Day 1 — July 23, 2026: The committee will review BPC-157, KPV, TB-500, and MOTS-c. This is the session most relevant to the healing and longevity research communities.

Day 2 — July 24, 2026: The committee will review Emideltide (DSIP), Semax, and Epitalon. These are the brain optimization and longevity peptides from the Russian bioregulator research tradition.

The hearing is open to the public. Both in-person and virtual attendance options are available. The venue is FDA White Oak Campus, 10903 New Hampshire Avenue, Silver Spring, MD 20993.

What the PCAC Does (and Doesn’t Do)

The PCAC is an advisory committee — its vote is a recommendation, not a binding decision. After the meeting, the FDA reviews the committee’s recommendation and decides whether to initiate formal rulemaking. If the FDA proceeds, it publishes a proposed rule, accepts a comment period, then publishes a final rule that officially adds the substance to the 503A bulks list.

This means that even a unanimous positive PCAC vote does not immediately authorize compounding. The full rulemaking process typically takes 12 to 24 months after the hearing. However, a positive vote is a strong indicator of eventual authorization, and historically the FDA generally follows PCAC recommendations.

Importantly, the PCAC recommendation also signals to FDA enforcement that the agency is unlikely to pursue enforcement actions against compounders who prepare these substances while the rulemaking process unfolds. The practical effect of a positive recommendation may therefore be felt sooner than the formal legal authorization.

The Evidence the FDA Is Weighing

For each peptide, the PCAC will consider: whether there is a clinical need for the compounded version, the current state of the safety evidence, quality and stability considerations for compounding, and public comments and oral testimony submitted through the docket.

BPC-157: Over 500 published preclinical studies across tendon, gut, cardiovascular, and neurological applications. No human clinical trials. No FDA-approved human drug equivalent.

TB-500 (Thymosin Beta-4 fragment Ac-SDKP): The active fragment of thymosin beta-4. Tissue repair, anti-fibrotic, and cellular mobilization properties documented in animal models. Used clinically in veterinary medicine.

MOTS-c: Mitochondrially-derived peptide that activates AMPK and regulates metabolic homeostasis. Expanding research base in insulin sensitivity, neuroprotection, and pancreatic islet cell senescence (Nature, 2025). No FDA-approved equivalent.

KPV: Tripeptide fragment of alpha-MSH. Anti-inflammatory properties well-documented in gut and skin applications. Studied in Crohn’s disease and IBD models.

DSIP (Emideltide): Delta sleep-inducing peptide. Studied for sleep architecture normalization and withdrawal management support.

Semax: Synthetic ACTH analogue developed in Russia. Neuroprotective and cognitive properties documented in preclinical research and some small human studies.

Epitalon: Tetrapeptide bioregulator derived from the pineal gland. Telomere elongation and anti-aging properties documented in animal models and limited human studies.

How to Participate

The public docket (FDA-2025-N-6895) is open at regulations.gov. Two ways to participate:

Written comments (recommended for most people): Submit via regulations.gov searching docket number FDA-2025-N-6895. Comments submitted by July 9, 2026 will be formally provided to PCAC members ahead of the meeting. Include: which peptide(s) you’re commenting on, your relationship to the research, and specific evidence or arguments you want the committee to consider.

Oral testimony (registration closes June 30): Individuals or organizations wishing to give a formal oral presentation must notify FDA by June 30, 2026. Notifications must include: a brief description of the evidence or arguments to be presented, the names and addresses of participants, whether you prefer in-person or virtual participation, and a requested time allotment. Contact FDA at the address listed in the Federal Register notice for docket FDA-2025-N-6895.

If you have clinical experience with any of these compounds, peer-reviewed citations supporting their safety profile, or documented evidence of patient need, your submission has genuine value to the process. The PCAC is not a political body — its members are scientific and clinical experts who weigh evidence. Quality submissions matter.

What a Positive Recommendation Means for Researchers

If the PCAC recommends BPC-157, TB-500, MOTS-c, and their co-reviewed peptides for the 503A bulks list, and the FDA follows through with rulemaking, the downstream effects are significant: licensed 503A compounding pharmacies would have a legal basis to prepare these compounds for individual patient prescriptions from physicians, under pharmaceutical-grade conditions (USP 795, Good Compounding Practices) with documented purity. Physicians prescribing these compounds would be operating in a legal framework rather than a grey zone.

The compounded product would differ from grey-market research peptides in one critical way: it would be prepared by a licensed compounder, with a valid physician prescription, for a specific patient. This eliminates most of the supply chain integrity risks that characterize the current grey market.

The Grey Market Context

The stakes of this hearing are not abstract. Chainalysis published data in June 2026 showing the grey-market peptide economy has crossed a $100 million annual run rate, with former fentanyl precursor manufacturers now among major suppliers. Independent purity testing participation has collapsed. For retatrutide specifically, 37 of 37 independently tested grey-market samples received failing purity grades.

When the PCAC votes on whether to recommend a lawful compounding pathway, they are voting on whether researchers who want quality-verified access to BPC-157 or TB-500 have a legal alternative to this supply chain. The outcome has direct practical consequences for safety.

Peptide Hub will publish a follow-up article immediately after the July 23–24 hearing with PCAC vote outcomes for each compound.

---

Editorial Note: This article is published for research and educational purposes only. Peptide Hub does not sell peptides, receive commissions from peptide vendors, or endorse any specific supplier. All compounds discussed are research peptides not approved for human therapeutic use except where specifically noted. This is not medical advice.

Sources: (1) Peptide Dossier, PCAC July 23–24 Hearing overview; (2) Orrick, “FDA Announces Removal of 12 Peptides from Category 2”; (3) Frier Levitt, “FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List”; (4) Lengea Law, “FDA Puts BPC-157, TB-500, and 5 Other Peptides Under the Microscope”; (5) Chainalysis, “Inside the $100M Gray Market Peptide Crypto Boom”; (6) FDA.gov docket FDA-2025-N-6895 at regulations.gov; (7) PBS NewsHour, “FDA to weigh easing limits on unproven peptides.”